News 05.09.2018 Financial highlights CHF 9.7 million cash at June 30 Operating expenses decreased to CHF 6.0 million Operational highlights First U.S. & European sales of MagnetOs Commercial rollout in the U.S. and Europe on track Preparation for Phase II clinical study of Fibrin-PTH in spine on track Download report
Internal events
Event date: 18.09.2018
Date: September 18th from 16:00 to 19:00
Place: Momento Caffè & Lounge
News 30.08.2018 Promising initial data from MP0250 combination with bortezomib (Velcade®) in phase 2 study in multiple myeloma: Five of eight evaluable patients achieved an objective response with median time of treatment for responding patients of 22.5 weeks. MP0250 combination with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cancer supported by...
News 27.08.2018 ProteoMediX AG, a diagnostic company developing blood-based tests for the accurate diagnosis and prognosis of prostate cancer, has announced the successful closing of an equity financing round. The company raised CHF 5.2 million (€ 4.6 million) from existing investors. Altos Venture (Allschwil, Switzerland), a Swiss venture capital firm chaired by Dr....
Internal events
Event date: 27.09.2018
Continuous bioprocessing is improving the process stability, flexibility and profitability of pharmaceutical manufacturing. Pall develops innovative solutions tailored to manufacturers needs implementing continuous manufacturing.
Place: Auditorium, Wagistrasse 25
Program:
08:45 - 09:00 Coffee & Croissants
09:00 - 09:45 Presentation: Continuous Bioprocessing in pharmaceutical manufacturing
10:00 - 12:00 Session 1: Clarification & sterile filtration /...